Abstract
Human embryonic stem cells have excellent potential for being the ultimate source of transplantable cells for many different tissues. To enable their clinical use, differentiation protocols should be developed and safety standards must be met. The cells should improve symptoms without generating side effects and their immune rejection must be overcome. Profiling of the immune antigens expressed on the cells has revealed that upon differentiation the cells express molecules of the major histocompatibility complex. Here, we propose ways of overcoming the rejection of human embryonic stem cells after transplantation.
| Original language | English |
|---|---|
| Pages (from-to) | 136-141 |
| Number of pages | 6 |
| Journal | Trends in Biotechnology |
| Volume | 22 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2004 |
Bibliographical note
Funding Information:We thank the members of our laboratory for critical review of the manuscript. This research was partially supported by funds from the Herbert Cohn Chair (Hebrew University).
